TEVA logo

TEVA EBITDA

annual EBITDA:

$690.00M-$868.00M(-55.71%)
December 31, 2024

Summary

  • As of today (May 31, 2025), TEVA annual EBITDA is $690.00 million, with the most recent change of -$868.00 million (-55.71%) on December 31, 2024.
  • During the last 3 years, TEVA annual EBITDA has fallen by -$2.19 billion (-76.03%).
  • TEVA annual EBITDA is now -87.33% below its all-time high of $5.45 billion, reached on December 31, 2014.

Performance

TEVA EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTEVAincome statement metrics

quarterly EBITDA:

$763.00M+$502.00M(+192.34%)
March 31, 2025

Summary

  • As of today (May 31, 2025), TEVA quarterly EBITDA is $763.00 million, with the most recent change of +$502.00 million (+192.34%) on March 31, 2025.
  • Over the past year, TEVA quarterly EBITDA has increased by +$708.00 million (+1287.27%).
  • TEVA quarterly EBITDA is now -62.45% below its all-time high of $2.03 billion, reached on March 31, 2018.

Performance

TEVA quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTEVAincome statement metrics

TTM EBITDA:

$1.49B+$708.00M(+91.12%)
March 31, 2025

Summary

  • As of today (May 31, 2025), TEVA TTM EBITDA is $1.49 billion, with the most recent change of +$708.00 million (+91.12%) on March 31, 2025.
  • Over the past year, TEVA TTM EBITDA has increased by +$164.00 million (+12.41%).
  • TEVA TTM EBITDA is now -72.73% below its all-time high of $5.45 billion, reached on December 31, 2014.

Performance

TEVA TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTEVAincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

TEVA EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-55.7%+1287.3%+12.4%
3 y3 years-76.0%+295.6%-11.6%
5 y5 years-46.0%+29.3%+14.9%

TEVA EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-76.0%+174.6%-23.2%+211.6%-23.1%+260.4%
5 y5-year-76.0%+135.4%-23.2%+119.3%-57.8%+165.9%
alltimeall time-87.3%+104.5%-62.5%+106.1%-72.7%+109.7%

TEVA EBITDA History

DateAnnualQuarterlyTTM
Mar 2025
-
$763.00M(+192.3%)
$1.49B(+91.1%)
Dec 2024
$690.00M(-55.7%)
$261.00M(+26.1%)
$777.00M(-48.5%)
Sep 2024
-
$207.00M(-18.5%)
$1.51B(-21.8%)
Jun 2024
-
$254.00M(+361.8%)
$1.93B(+46.1%)
Mar 2024
-
$55.00M(-94.5%)
$1.32B(-15.2%)
Dec 2023
$1.56B(-268.4%)
$994.00M(+58.5%)
$1.56B(-1398.3%)
Sep 2023
-
$627.00M(-276.6%)
-$120.00M(+1400.0%)
Jun 2023
-
-$355.00M(-221.6%)
-$8.00M(-96.7%)
Mar 2023
-
$292.00M(-142.7%)
-$244.00M(-73.7%)
Dec 2022
-$925.00M(-132.1%)
-$684.00M(-192.6%)
-$926.00M(+8318.2%)
Sep 2022
-
$739.00M(-225.0%)
-$11.00M(-105.4%)
Jun 2022
-
-$591.00M(+51.5%)
$202.00M(-88.0%)
Mar 2022
-
-$390.00M(-268.8%)
$1.68B(-41.7%)
Dec 2021
$2.88B(-247.8%)
$231.00M(-75.7%)
$2.88B(-18.1%)
Sep 2021
-
$952.00M(+7.3%)
$3.52B(-351.9%)
Jun 2021
-
$887.00M(+9.5%)
-$1.40B(-19.3%)
Mar 2021
-
$810.00M(-6.7%)
-$1.73B(-11.3%)
Dec 2020
-$1.95B(-252.3%)
$868.00M(-121.9%)
-$1.95B(-13.5%)
Sep 2020
-
-$3.96B(-815.0%)
-$2.25B(-210.4%)
Jun 2020
-
$554.00M(-6.1%)
$2.04B(+57.9%)
Mar 2020
-
$590.00M(+4.6%)
$1.29B(+1.0%)
Dec 2019
$1.28B(+670.5%)
$564.00M(+69.9%)
$1.28B(-160.7%)
Sep 2019
-
$332.00M(-271.1%)
-$2.11B(+8.1%)
Jun 2019
-
-$194.00M(-133.6%)
-$1.95B(+51.1%)
Mar 2019
-
$577.00M(-120.5%)
-$1.29B(-876.5%)
Dec 2018
$166.00M(-101.1%)
-$2.82B(-675.7%)
$166.00M(-101.7%)
Sep 2018
-
$490.00M(+5.4%)
-$9.52B(+4.6%)
Jun 2018
-
$465.00M(-77.1%)
-$9.11B(-38.2%)
Mar 2018
-
$2.03B(-116.2%)
-$14.73B(-4.3%)
Dec 2017
-$15.39B(-631.9%)
-$12.51B(-1482.2%)
-$15.39B(+343.3%)
Sep 2017
-
$905.00M(-117.5%)
-$3.47B(-3.9%)
Jun 2017
-
-$5.16B(-475.5%)
-$3.61B(-288.9%)
Mar 2017
-
$1.38B(-333.4%)
$1.91B(-4.7%)
Dec 2016
$2.89B(-26.4%)
-$589.00M(-177.0%)
$2.01B(-35.9%)
Sep 2016
-
$765.00M(+111.9%)
$3.13B(-15.2%)
Jun 2016
-
$361.00M(-75.4%)
$3.69B(-14.5%)
Mar 2016
-
$1.47B(+174.3%)
$4.32B(+9.8%)
Dec 2015
$3.93B(-27.8%)
$536.00M(-59.5%)
$3.93B(-16.2%)
Sep 2015
-
$1.32B(+34.5%)
$4.69B(-3.1%)
Jun 2015
-
$985.00M(-9.1%)
$4.84B(-6.1%)
Mar 2015
-
$1.08B(-16.5%)
$5.15B(-5.4%)
Dec 2014
$5.45B(+69.9%)
$1.30B(-11.9%)
$5.45B(+7.6%)
Sep 2014
-
$1.47B(+13.4%)
$5.06B(+5.3%)
Jun 2014
-
$1.30B(-5.6%)
$4.81B(+44.7%)
Mar 2014
-
$1.38B(+51.0%)
$3.32B(+3.6%)
Dec 2013
$3.21B(-17.4%)
$911.00M(-25.3%)
$3.21B(+7.3%)
Sep 2013
-
$1.22B(-755.9%)
$2.99B(+41.0%)
Jun 2013
-
-$186.00M(-114.8%)
$2.12B(-42.7%)
Mar 2013
-
$1.26B(+82.2%)
$3.70B(-4.8%)
Dec 2012
$3.88B(-8.9%)
$692.00M(+96.6%)
$3.88B(-7.9%)
Sep 2012
-
$352.00M(-74.7%)
$4.21B(-18.1%)
Jun 2012
-
$1.39B(-3.9%)
$5.14B(+6.2%)
Mar 2012
-
$1.45B(+41.4%)
$4.84B(+6.9%)
Dec 2011
$4.26B(-11.7%)
$1.02B(-20.2%)
$4.53B(+0.5%)
Sep 2011
-
$1.28B(+17.3%)
$4.51B(-3.5%)
Jun 2011
-
$1.09B(-3.5%)
$4.67B(-4.4%)
Mar 2011
-
$1.13B(+13.2%)
$4.89B(+1.3%)
Dec 2010
$4.83B(+45.6%)
$1.00B(-30.8%)
$4.83B(+7.8%)
Sep 2010
-
$1.45B(+10.6%)
$4.48B(+10.9%)
Jun 2010
-
$1.31B(+22.4%)
$4.04B(+17.7%)
Mar 2010
-
$1.07B(+64.0%)
$3.43B(+18.3%)
Dec 2009
$3.31B(+102.3%)
$652.00M(-35.3%)
$2.90B(+87.9%)
Sep 2009
-
$1.01B(+43.4%)
$1.54B(+17.5%)
Jun 2009
-
$702.00M(+30.5%)
$1.31B(-4.2%)
Mar 2009
-
$538.00M(-176.4%)
$1.37B(-16.3%)
Dec 2008
$1.64B(-43.8%)
-$704.00M(-190.6%)
$1.64B(-47.9%)
Sep 2008
-
$777.00M(+2.2%)
$3.14B(+0.4%)
Jun 2008
-
$760.00M(-5.6%)
$3.13B(-0.2%)
Mar 2008
-
$805.00M(+0.5%)
$3.14B(+7.6%)
Dec 2007
$2.92B(+15.4%)
$801.00M(+4.7%)
$2.92B(+10.4%)
Sep 2007
-
$765.00M(-0.3%)
$2.64B(-2.5%)
Jun 2007
-
$767.00M(+31.6%)
$2.71B(-1.4%)
Mar 2007
-
$583.00M(+10.7%)
$2.75B(+7.4%)
Dec 2006
$2.53B(+62.5%)
$526.80M(-36.8%)
$2.56B(+7.0%)
Sep 2006
-
$833.70M(+3.6%)
$2.39B(+27.9%)
Jun 2006
-
$805.10M(+104.9%)
$1.87B(+36.1%)
Mar 2006
-
$393.00M(+9.1%)
$1.37B(+0.5%)
Dec 2005
$1.55B
$360.30M(+15.4%)
$1.37B(+1.8%)
Sep 2005
-
$312.20M(+1.2%)
$1.34B(-0.4%)
DateAnnualQuarterlyTTM
Jun 2005
-
$308.60M(-20.1%)
$1.35B(+0.9%)
Mar 2005
-
$386.40M(+15.0%)
$1.34B(+13.8%)
Dec 2004
$1.39B(+37.6%)
$336.00M(+5.8%)
$1.18B(+10.3%)
Sep 2004
-
$317.70M(+6.9%)
$1.07B(+12.8%)
Jun 2004
-
$297.10M(+32.5%)
$944.90M(+1.6%)
Mar 2004
-
$224.20M(-1.0%)
$929.70M(+5.1%)
Dec 2003
$1.01B(+63.1%)
$226.50M(+14.9%)
$884.80M(+5.2%)
Sep 2003
-
$197.10M(-30.1%)
$840.90M(+9.9%)
Jun 2003
-
$281.90M(+57.2%)
$765.40M(+28.6%)
Mar 2003
-
$179.30M(-1.8%)
$595.10M(+13.6%)
Dec 2002
$620.90M(+27.9%)
$182.60M(+50.2%)
$524.00M(+15.6%)
Sep 2002
-
$121.60M(+9.0%)
$453.16M(+5.2%)
Jun 2002
-
$111.60M(+3.1%)
$430.56M(+6.1%)
Mar 2002
-
$108.20M(-3.2%)
$405.81M(+7.8%)
Dec 2001
$485.58M(+3.3%)
$111.76M(+12.9%)
$376.51M(-14.6%)
Sep 2001
-
$99.00M(+14.0%)
$440.71M(+5.9%)
Jun 2001
-
$86.85M(+10.1%)
$416.13M(-1.6%)
Mar 2001
-
$78.90M(-55.2%)
$422.74M(+5.7%)
Dec 2000
$470.19M(+40.0%)
$175.95M(+136.4%)
$399.83M(+13.0%)
Sep 2000
-
$74.42M(-20.4%)
$353.94M(+6.9%)
Jun 2000
-
$93.46M(+66.9%)
$331.17M(+17.2%)
Mar 2000
-
$56.00M(-56.9%)
$282.45M(+5.6%)
Dec 1999
$335.89M(+28.0%)
$130.07M(+151.9%)
$267.37M(+10.5%)
Sep 1999
-
$51.64M(+15.4%)
$241.94M(+5.2%)
Jun 1999
-
$44.74M(+9.3%)
$229.99M(+10.1%)
Mar 1999
-
$40.92M(-60.9%)
$208.85M(+2.6%)
Dec 1998
$262.48M(+16.2%)
$104.63M(+163.6%)
$203.53M(-136.9%)
Sep 1998
-
$39.70M(+68.2%)
-$552.30M(+80.9%)
Jun 1998
-
$23.60M(-33.7%)
-$305.30M(+424.5%)
Mar 1998
-
$35.60M(-105.5%)
-$58.20M(-133.5%)
Dec 1997
$225.80M(+30.5%)
-$651.20M(-327.1%)
$173.80M(-37.5%)
Sep 1997
-
$286.70M(+5.9%)
$278.20M(+22.0%)
Jun 1997
-
$270.70M(+1.2%)
$228.10M(+9.9%)
Mar 1997
-
$267.60M(-148.9%)
$207.60M(+60.6%)
Dec 1996
$173.00M(+26.1%)
-$546.80M(-331.1%)
$129.30M(-57.7%)
Sep 1996
-
$236.60M(-5.4%)
$305.50M(+30.4%)
Jun 1996
-
$250.20M(+32.2%)
$234.20M(+66.3%)
Mar 1996
-
$189.30M(-151.1%)
$140.80M(+35.1%)
Dec 1995
$137.20M(+2.2%)
-$370.60M(-324.2%)
$104.20M(-31.1%)
Sep 1995
-
$165.30M(+5.4%)
$151.20M(+16.8%)
Jun 1995
-
$156.80M(+2.7%)
$129.40M(+8.3%)
Mar 1995
-
$152.70M(-147.2%)
$119.50M(+15.5%)
Dec 1994
$134.30M(+24.8%)
-$323.60M(-325.5%)
$103.50M(-28.3%)
Sep 1994
-
$143.50M(-2.3%)
$144.40M(+12.7%)
Jun 1994
-
$146.90M(+7.5%)
$128.10M(+20.6%)
Mar 1994
-
$136.70M(-148.4%)
$106.20M(+20.8%)
Dec 1993
$107.60M(+47.8%)
-$282.70M(-322.2%)
$87.90M(-41.6%)
Sep 1993
-
$127.20M(+1.8%)
$150.50M(+29.4%)
Jun 1993
-
$125.00M(+5.6%)
$116.30M(+38.0%)
Mar 1993
-
$118.40M(-153.8%)
$84.30M(+43.4%)
Dec 1992
$72.80M(+10.5%)
-$220.10M(-336.7%)
$58.80M(-32.1%)
Sep 1992
-
$93.00M(0.0%)
$86.60M(+19.8%)
Jun 1992
-
$93.00M(+0.1%)
$72.30M(+26.6%)
Mar 1992
-
$92.90M(-148.3%)
$57.10M(+10.9%)
Dec 1991
$65.90M(+24.6%)
-$192.30M(-344.3%)
$51.50M(-45.8%)
Sep 1991
-
$78.70M(+1.2%)
$95.00M(+20.4%)
Jun 1991
-
$77.80M(-10.9%)
$78.90M(+11.6%)
Mar 1991
-
$87.30M(-158.7%)
$70.70M(+44.0%)
Dec 1990
$52.90M(+19.4%)
-$148.80M(-337.7%)
$49.10M(+6.0%)
Sep 1990
-
$62.60M(-10.1%)
$46.30M(-2.5%)
Jun 1990
-
$69.60M(+5.9%)
$47.50M(+1.7%)
Mar 1990
-
$65.70M(-143.3%)
$46.70M(-5.1%)
Dec 1989
$44.30M(+46.2%)
-$151.60M(-337.6%)
$49.20M(-37.4%)
Sep 1989
-
$63.80M(-7.3%)
$78.60M(+28.0%)
Jun 1989
-
$68.80M(+0.9%)
$61.40M(+43.8%)
Mar 1989
-
$68.20M(-155.8%)
$42.70M(+74.3%)
Dec 1988
$30.30M(+24.2%)
-$122.20M(-362.2%)
$24.50M(-83.3%)
Sep 1988
-
$46.60M(-7.0%)
$146.70M(+14.1%)
Jun 1988
-
$50.10M(+0.2%)
$128.60M(+22.6%)
Mar 1988
-
$50.00M(+75.4%)
$104.90M(+2284.1%)
Sep 1987
-
$28.50M(+8.0%)
$4.40M(-59.3%)
Jun 1987
-
$26.40M(-130.9%)
$10.80M(-44.0%)
Mar 1987
$24.40M(+58.4%)
-$85.40M(-344.7%)
$19.30M(-60.0%)
Dec 1986
-
$34.90M(0.0%)
$48.20M(+33.5%)
Sep 1986
-
$34.90M(0.0%)
$36.10M(+50.4%)
Jun 1986
-
$34.90M(-161.8%)
$24.00M(+101.7%)
Mar 1986
$15.40M
-$56.50M(-347.8%)
$11.90M(-82.6%)
Dec 1985
-
$22.80M(0.0%)
$68.40M(+50.0%)
Sep 1985
-
$22.80M(0.0%)
$45.60M(+100.0%)
Jun 1985
-
$22.80M
$22.80M

FAQ

  • What is Teva Pharmaceutical Industries Limited annual EBITDA?
  • What is the all time high annual EBITDA for Teva Pharmaceutical Industries Limited?
  • What is Teva Pharmaceutical Industries Limited annual EBITDA year-on-year change?
  • What is Teva Pharmaceutical Industries Limited quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Teva Pharmaceutical Industries Limited?
  • What is Teva Pharmaceutical Industries Limited quarterly EBITDA year-on-year change?
  • What is Teva Pharmaceutical Industries Limited TTM EBITDA?
  • What is the all time high TTM EBITDA for Teva Pharmaceutical Industries Limited?
  • What is Teva Pharmaceutical Industries Limited TTM EBITDA year-on-year change?

What is Teva Pharmaceutical Industries Limited annual EBITDA?

The current annual EBITDA of TEVA is $690.00M

What is the all time high annual EBITDA for Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited all-time high annual EBITDA is $5.45B

What is Teva Pharmaceutical Industries Limited annual EBITDA year-on-year change?

Over the past year, TEVA annual EBITDA has changed by -$868.00M (-55.71%)

What is Teva Pharmaceutical Industries Limited quarterly EBITDA?

The current quarterly EBITDA of TEVA is $763.00M

What is the all time high quarterly EBITDA for Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited all-time high quarterly EBITDA is $2.03B

What is Teva Pharmaceutical Industries Limited quarterly EBITDA year-on-year change?

Over the past year, TEVA quarterly EBITDA has changed by +$708.00M (+1287.27%)

What is Teva Pharmaceutical Industries Limited TTM EBITDA?

The current TTM EBITDA of TEVA is $1.49B

What is the all time high TTM EBITDA for Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited all-time high TTM EBITDA is $5.45B

What is Teva Pharmaceutical Industries Limited TTM EBITDA year-on-year change?

Over the past year, TEVA TTM EBITDA has changed by +$164.00M (+12.41%)
On this page